Abstract
Emerging and re-emerging viral infections pose a major challenge to global health due to their ability to evade host immunity and induce systemic alterations. Coronaviruses and flaviviruses are particularly efficient at disrupting innate and adaptive immune pathways through viral proteins that promote immune evasion, viral persistence, and inflammatory, coagulopathic, and neurodegenerative outcomes. This PhD thesis presents key scientific themes related to emerging RNA viruses and details my direct contributions to study design, analysis, and interpretation. I highlight my role in conceptualizing, writing, and critically revising reviews and original articles on innate immunity, neurodegeneration, and virus-associated coagulopathies. The first research line focused on immune dysregulation and neurodegenerative consequences of SARS-CoV-2 and flavivirus infections. For SARS-CoV-2, my work demonstrated the central role of NK cells, macrophages, monocytes, and neutrophils in early antiviral responses and how the virus disrupts this balance, leading to hyperinflammation or immune exhaustion. I also showed that vaccination activates NK cells—especially CD56^dim cells—promoting memory-like cytotoxic features effective across variants. Additionally, I documented the involvement of HLA-G and HLA-E in immune escape and viral persistence. I investigated ADAM17 as a host factor regulating SARS-CoV-2 infection, demonstrating that its inhibition with JG26 reduces ACE2 shedding and viral replication in lung epithelial cells, identifying a promising host-directed antiviral strategy. Extending the research to flaviviruses, I explored how soluble NS1 proteins from Dengue, West Nile (WNV), and Zika (ZIKV) modulate innate immunity. I showed that Dengue sNS1 activates TLR4-dependent inflammatory pathways in microglia, while WNV and ZIKV sNS1 trigger TLR3-mediated antiviral and proinflammatory responses that may disrupt the blood–brain barrier and contribute to neurodevelopmental complications. A key finding was that WNV NS1 induces glial activation and Aβ accumulation, connecting flavivirus infection to neurodegeneration. The second major research line addressed virus-induced coagulopathies. I identified a marked reduction of protein S (PROS1) in COVID-19 patients with coagulopathy, likely caused by cleavage via PLpro, linking viral enzymatic activity to thrombo-inflammation and indicating PLpro as a therapeutic target. I also contributed to showing that flavivirus NS1 differentially modulates coagulation: neurotropic viruses increase tissue factor expression and procoagulant microvesicles, whereas Dengue NS1 exerts anticoagulant effects, with IL-6 as a key mediator. Together, these findings support a unifying model in which SARS-CoV-2 and flaviviruses exploit viral proteins such as PLpro and NS1 to manipulate host immunity, promoting endothelial injury, coagulation abnormalities, and neurodegeneration. Beyond these core projects, I contributed to studies on host-directed interventions, including the use of a ketone diester to modulate NLRP3 inflammasome activation in microglia and the effects of ozonated oil in liposomal eyedrops on bacterial biofilms and antibiotic resistance. I also performed comparative analyses of moxifloxacin and chloramphenicol efficacy in bacterial eye infections, providing insights into optimized therapeutic approaches. Finally, I authored the review “Immune Modulation by Microbiota and Its Possible Impact on Polyomavirus Infection,” in which I independently synthesized existing evidence to propose an integrated model describing how microbiota-mediated immune regulation shapes polyomavirus infection outcomes and vice versa. This work advances the conceptual framework for future system-level studies on virus–host interactions and supports the development of innovative antiviral and immunomodulatory strategies.